Carl L. Gordon - Oct 6, 2021 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role: Director, 10%+ Owner
Signature: /s/ Bradford Dahms - Attorney-in-Fact
Stock symbol: THRX
Transactions as of: Oct 6, 2021
Transactions value $: $0
Form type: 4
Date filed: 10/8/2021, 07:00 PM
Previous filing: Oct 6, 2021
Next filing: Oct 14, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	THRX	Stock Option (right to buy)	Award	$0	+22.7K		$0.00	22.7K	Oct 6, 2021	Common Stock	22.7K	$16.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/36th of the options vesting monthly after October 6, 2021, subject to the Reporting Person's continuous service with the issuer. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.

Content

The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/36th of the options vesting monthly after October 6, 2021, subject to the Reporting Person's continuous service with the issuer. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.